Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Acadia Pharmaceuticals Inc. (ACAD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.76, with a market capitalisation of $4.74B and a P/E ratio of 12.12. Over the past 52 weeks, its price has ranged from $19.69 to $30.96. This page covers its latest market performance, valuation, price trends and company information.
$4.74B | |
$26.76 | |
$58.72 | |
$0.65 | |
$26.76 | |
24.00 | |
1.67M | |
12.12 | |
$30.96 | |
$19.69 | |
-- | |
-- |
Acadia Pharmaceuticals Inc. (ACAD) is trading at $26.76 in pre-market trading as of 2026-09-16 08:03:00, unchanged from the previous close of $26.76
Pre-market trading shows how investors are pricing ACAD before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Acadia Pharmaceuticals Inc. (ACAD) moved from $28.02 to $26.76, representing a decline of 4.50% ($1.26).
The stock traded between $26.64 and $28.24 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.34 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 62.7%
ACAD is currently trading at $26.76, placing it 62.7% of the way from its 52-week low of $19.69 to its 52-week high of $30.96. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 798 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Acadia Pharmaceuticals Inc. (ACAD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.